Abstract
Aberrant epithelial differentiation and regeneration pathways contribute to colon pathologies including inflammatory bowel disease (IBD) and colitis-associated cancer (CAC). MTG16 (also known as CBFA2T3) is a transcriptional corepressor expressed in the colonic epithelium. MTG16 interaction partners include E box-binding basic helix-loop-helix transcription factors (E proteins). MTG16-deficient mice exhibit worse colitis and increased tumor burden in inflammatory carcinogenesis. In this study, we sought to understand the role of MTG16 colonic epithelial homeostasis and the mechanisms by which MTG16 protects the epithelium in colitis and CAC. We demonstrated that MTG16 deficiency enabled enteroendocrine cell differentiation from secretory precursor cells at the expense of goblet cells. Transcriptomic analysis implicated dysregulated E protein function in MTG16-deficient colon crypts. Using a novel mouse model with a point mutation that disrupts MTG16:E protein complex formation (Mtg16P209T), we established that enteroendocrine:goblet cell balance was dependent on MTG16:E protein interactions and that the shift in lineage allocation was associated with enhanced expression of Neurog3, the central driver of enteroendocrine lineage specification. Furthermore, Mtg16 was upregulated in the previously described Ascl2+, de-differentiating cells that replenish the stem cell compartment in response to colon injury. Mtg16 expression was also increased in dextran sulfate sodium (DSS)-treated mouse colon crypts and in IBD patients compared to unaffected controls. We determined that the effects of MTG16 in regeneration are also dependent on its repression of E proteins, as the colonic epithelium failed to regenerate following DSS-induced injury in our novel mutant mouse model. Finally, we revealed that uncoupling MTG16:E protein interactions contributes to the enhanced tumorigenicity in Mtg16-/- colon in the azoxymethane(AOM)/DSS-induced model of CAC. Collectively, our results demonstrate that MTG16, via its repression of E protein targets, is a key regulator of cell fate decisions during colonic differentiation and regeneration.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
Grant Support This work was supported by the National Institutes of Health (F30DK120149 to REB, F31DK127687 to PNV, F31CA232272 to JMP, R01DK103831 to KSL, U01CA215798 to KSL, R03DK123489 to JAG, R01CA178030 to SWH, K01DK123495 to SPS, F32DK108492 to SPS, R01DK099204 to CSW, P30DK058404 to the Vanderbilt Digestive Disease Research Center [DDRC], P50CA236733 to the Vanderbilt-Ingram Cancer Center [VICC] Spore in Gastrointestinal Cancer, and T32GM00734 to the Vanderbilt Medical Scientist Training Program), the U.S. Department of Veterans Affairs Office of Medical Research (1I01BX001426 to CSW and IK2BX004648 to YAC), the Crohn’s and Colitis Foundation (623541 to CSW and 662877 to SPS), the Royal Netherlands Academy of Arts and Sciences (Academy Ter Meulen Grant to JJ), and the Prince Bernhard Cultural Foundation (Cultural Foundation Grant to JJ). KP was supported by grants from Academy of Finland (Finnish Center of Excellence Program 2018–2025, 312041), the iCAN Digital Precision Cancer Medicine Flagship (320185), and the Sigrid Jusélius Foundation. YAC was also supported by the P30DK058404 Vanderbilt DDRC Pilot and Feasibility grant. The Vanderbilt Translational Pathology Shared Resource (TPSR) was supported by NCI/NIH Cancer Center Support Grant 2P30CA068485-14 and the Vanderbilt Mouse Metabolic Phenotyping Center Grant 5U24DK059637-13.
Disclosures The authors declare no competing interests.